The
global Biomarkers
Market size
is expected to reach USD 194.21 billion by 2030, registering a CAGR of 13.36%
from 2024 to 2030, according to a new report by Grand View Research, Inc. The
rising R&D investments by pharmaceutical and biotechnology companies,
increasing number of Contract Research Organizations(CROs), and declining cost
of clinical trials in emerging economies are the major driving factors for the
industry. In addition, key players leverage various strategies to increase
their production capabilities and promote the outreach of their product
offerings. In June 2022, Paige announced its collaboration with Janssen to
evaluate the potential of an (H&E)-based, (AI)-powered biomarker test,
developed by Janssen, to screen for actionable FGFR3 and FGFR2 genomic
alterations in patients with bladder cancer.
The
increasing prevalence of chronic diseases like cancer, diabetes, and
cardiovascular disorders is anticipated to fuel industry growth. According to
the American Cancer Society, in 2022, an estimated 1.9 million new cancer cases
were registered in the U.S., accounting for 609,360 deaths. Breast and lung
cancers were observed as the most common ones worldwide. In addition, according
to a report published in 2020 by the Institute for Health Metrics and
Evaluation, cardiovascular diseases cause about 18.9 million deaths annually.
Increasing research focused on the identification of new diagnostic biomarkers
is fueling the industry's growth. For instance, in February 2022, Japanese
scientists found two new diagnostic tissue biomarkers, PHGDH and TRIM29,
indicated for malignant pleural mesothelioma.
These
agents can be used to diagnose mesothelioma quickly and help doctors in
differentiating between mesothelioma and other cancers. Moreover, in January
2020, a nascent research study published in the Journal of Nuclear Medicine
discussed the potential of several breast cancer biomarkers. A notable and
easily identifiable imaging biomarker recognized in the study was 18F-FDG PET.
Moreover, the COVID-19 pandemic has encouraged the use of biomarkers for
facilitating the detection & treatment of the disease. For instance, in
March 2021, a new biomarker-based screening device, named Tiger Tech COVID Plus
Monitor, was approved by the U.S. FDA.
The
device can be used for the identification of biomarkers for COVID-19 and other
hypercoagulable & hyperinflammatory conditions in individuals aged 5 years
& above. Furthermore, various strategic initiatives undertaken by leading
participants are anticipated to cater to demand. For instance, in August 2022,
Roche received the U.S. FDA approval for VENTANA MMR RxDx Panel to detect pMMR
endometrial cancer patients and dMMR solid tumor patients eligible for
treatment with Merck’s immunotherapy Keytruda. This approval for the VENTANA
MMR RxDx Panel is a label expansion of the company’s recent on-market panel.
Also, in December 2021, Siemens Healthineers partnered with Freenome to
identify novel suitable markers for the detection of early breast cancer to
expand its existing imaging technologies.
Related Press
Release@ Biomarkers
Market Report
Biomarkers Market Report Highlights
- The safety
segment held the largest revenue share of 37.62% in 2023 owing to the
increased adoption of safety biomarkers in drug discovery and development
- The efficacy
biomarkers segment is expected to grow at the fastest CAGR from 2024 to
2030 due to a rise in strategic collaborations for promoting research
activities
- The drug
discovery & development segment dominated the market in 2023 due to
the extensive R&D efforts taken by leading participants, and the
rising adoption of biomarkers in drug discovery
- The cancer
segment led the market in 2023 and is expected to retain its dominance
from 2024 to 2030. . However, the neurological diseases segment is
anticipated to record the fastest CAGR over the forecast years
- Asia Pacific
is anticipated to attain the fastest CAGR from 2024 to 2030 due to the
rising investments by key players and increasing disease prevalence in the
region
Biomarkers Market Report Scope
Report Attribute |
Details |
Market
size value in 2024 |
USD 91.52
billion |
Revenue
forecast in 2030 |
USD
194.21 billion |
Growth
rate |
CAGR of
13.36% from 2023 to 2030 |
Historical
data |
2023 |
Actual data |
2018 - 2022 |
Forecast period |
2024 - 2030 |
Request For A Free Consultation @ https://www.grandviewresearch.com/request-free-consultation/70/rfc
Biomarkers Market Segmentation
Grand
View Research has segmented the global biomarkers market on the basis of on
type, product, application, disease, and region:
Biomarkers Type Outlook (Revenue, USD Million, 2018 -
2030)
- Safety
Biomarkers
- Efficacy
Biomarkers
- Predictive
Biomarkers
- Surrogate
Biomarkers
- Pharmacodynamic
Biomarkers
- Prognostics
Biomarkers
- Validation Biomarkers
Biomarkers Product Outlook (Revenue, USD Million, 2018 -
2030)
- Consumable
- Services
- Software
Biomarkers Application Outlook (Revenue, USD Million,
2018 - 2030)
- Diagnostics
- Drug
Discovery & Development
- Personalized
Medicine
- Disease Risk
Assessment
- Others
Biomarkers Disease Outlook (Revenue, USD Million, 2018 -
2030)
- Cancer
- Safety
Biomarkers
- Efficacy
Biomarkers
- Predictive
Biomarkers
- Surrogate
Biomarkers
- Pharmacodynamic
Biomarkers
- Prognostics
Biomarkers
- Validation
Biomarkers
- Cardiovascular
Diseases
- Safety
Biomarkers
- Efficacy
Biomarkers
- Predictive
Biomarkers
- Surrogate
Biomarkers
- Pharmacodynamic
Biomarkers
- Prognostics
Biomarkers
- Validation
Biomarkers
- Neurological
Diseases
- Safety
Biomarkers
- Efficacy
Biomarkers
- Predictive
Biomarkers
- Surrogate
Biomarkers
- Pharmacodynamic
Biomarkers
- Prognostics
Biomarkers
- Validation
Biomarkers
- Immunological
Diseases
- Safety
Biomarkers
- Efficacy
Biomarkers
- Predictive
Biomarkers
- Surrogate
Biomarkers
- Pharmacodynamic
Biomarkers
- Prognostics
Biomarkers
- Validation
Biomarkers
- Others
- Safety
Biomarkers
- Efficacy
Biomarkers
- Predictive
Biomarkers
- Surrogate
Biomarkers
- Pharmacodynamic
Biomarkers
- Prognostics
Biomarkers
- Validation
Biomarkers
Biomarkers Regional Outlook (Revenue, USD Million, 2018 -
2030)
- North
America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- Latin
America
- Brazil
- Mexico
- Argentina
- Middle East
& Africa
- South
Africa
- Saudi
Arabia
- UAE
- Kuwait
About
Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment